The Prenatal Diagnostic Opportunity in VA and IHS

Bottom Line:

Manufacturers of prenatal diagnostics who look at the VA and the IHS see two agencies with almost no internal maternity footprint and conclude there is nothing to sell into. The opposite is true. Both agencies deliver maternity care through community providers - clinicians manufacturers are frequently already calling on — which means the volume is not absent, it is unrecognized. The work is in identifying it and getting paid correctly for it.

For manufacturers of non-invasive prenatal testing, carrier screening panels, and specialized reference laboratory services, federal strategy tends to begin and end with the Department of Defense. TRICARE offers a defined beneficiary population and an obstetric footprint inside military treatment facilities. It is a recognizable market, and it absorbs the entire federal conversation.

The Department of Veterans Affairs and the Indian Health Service are usually dismissed on the assumption that neither delivers babies. That assumption is correct, and it is the wrong thing to conclude from.

Neither agency delivers maternity care. Both pay for it.

The VA operates no labor and delivery units. Maternity care for enrolled Veterans is authorized out to community obstetricians and delivered in community hospitals. The IHS routes obstetric patients — particularly high-risk ones — to non-IHS facilities through Purchased/Referred Care, and a substantial share of the AI/AN birthing population receives care outside the direct IHS system entirely.

The implication is not that these are closed markets. It is that they are invisible ones. The obstetrician ordering the assay is a community provider, likely already in a manufacturer's commercial territory. The specimen is already being drawn. The test is already being run. What is different is upstream and downstream of the clinician: authorization runs through VA Community Care or IHS Purchased/Referred Care, each with its own referral requirements, timelines, and payer identification — and none of it looks like a commercial claim at intake.

This is where the Federal Supply Schedule assumption misleads. FSS governs what federal facilities purchase and stock. A send-out assay performed for a community-referred patient does not move through the schedule; it moves through Community Care or PRC. Manufacturers who map their federal approach to FSS are preparing for a transaction that is not the one occurring.

What this changes about the sales motion

It makes it smaller, and it makes it more achievable.

A manufacturer does not need a federal sales team to reach these patients. The clinicians are already covered. What is required is a set of targeted modifications to infrastructure that already exists:

Intake and billing. Can the organization distinguish a VA Community Care or IHS PRC episode from a commercial one at the point of order? If not, those claims are being coded, worked, and written off as though they were something else. The denial and write-off rate on that volume is the first number worth pulling, because it is knowable this quarter and it is almost certainly worse than the commercial baseline.

Field awareness. Commercial reps working accounts near VA medical centers, in states with large Veteran populations, or in and around tribal service areas are already touching this volume without labeling it. They cannot ask about a payment pathway they have never been told exists.

Prior authorization. Community Care and PRC have referral windows and authorization requirements that commercial workflows are not built to respect. A missed window is an unpaid test on a specimen already consumed.

The tribal health caution

Any manufacturer approaching IHS or tribal health systems with a genetics product should be prepared to speak to data governance before being asked. Variant classification pipelines rest on reference databases in which AI/AN populations are severely underrepresented, which raises variant-of-uncertain-significance rates and weakens predictive value. A manufacturer who can name this problem and describe what they are doing about specimen and data stewardship is in a materially different position than one who has not considered it.

Key Questions

• Are commercial reps in Veteran-dense and tribal-adjacent territories equipped to recognize these referral pathways in accounts they already cover?

• Do the prior authorization workflows respect Community Care and PRC referral windows, or are they built exclusively for commercial payers?

• Can the clinical materials survive a clinician's reading — or do they borrow a maternal health narrative the product does not address?